Another GCI exec leaves the SF fold

SAN FRANCISCO: GCI Group SVP Paul Laland, who founded and has led the firm's global biotech practice since 1999, has left his post to join gene therapy company Deltagen as VP of communications.

SAN FRANCISCO: GCI Group SVP Paul Laland, who founded and has led the firm's global biotech practice since 1999, has left his post to join gene therapy company Deltagen as VP of communications.

SAN FRANCISCO: GCI Group SVP Paul Laland, who founded and has led the firm's global biotech practice since 1999, has left his post to join gene therapy company Deltagen as VP of communications.

Laland cited personal reasons, including 'a need for more flexible hours,' for his decision. He also confirmed that two SVPs from the San Francisco-based biotech team, Rick Roose and Nina Ferrari, will take over his previous responsibilities.

In a role that is new to the company, Laland will oversee PR and IR for Deltagen, an ongoing GCI client.

Formerly director of corporate communications for Genentech, Laland joined GCI/San Francisco in July 1999. Under his stewardship, the biotech/medical tech group has grown to more than 16 employees in San Francisco and New York, serving such clients as Chiron, mClone and Human Genome Sciences.

Laland is the second senior-level executive to exit GCI's San Francisco branch so far this year. Since Sam Singer stepped down as managing director in January, operations there have lacked full-time leadership. However, GCI North America president Bob Pearson said the firm is very close to filling the vacant position.

Recently, GCI SF hired Gary Good as SVP, to head the tech practice. He joined from Fleishman-Hillard, where he was a VP leading the telecom group.





Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in